I have invested in IMMU for many years. You are definitely mistaken to believe that Trodelvy is only a drug to be used after 3 failures of other drugs for mTNBC. Though that is the current label, the on-going research and trial results are pointing to much much more. Gilead will be getting a serious bargain if they can get it for only $20 billion. I believe CYDY has the same potential. That is why I’m long in it also. But I think it has a way to go. It would be great if it can see the fast rise that IMMU experienced this year. That rise came about because of one event (the stoppage of a trial for efficacy) that led to other events. I think the same can/will happen for CYDY.